126 related articles for article (PubMed ID: 35263093)
1. Self-Fluorescent Lone Tryptophan Nanoparticles as Theranostic Agents Against Alzheimer's Disease.
Sharma M; Tiwari V; Chaturvedi S; Wahajuddin M; Shukla S; Panda JJ
ACS Appl Mater Interfaces; 2022 Mar; 14(11):13079-13093. PubMed ID: 35263093
[TBL] [Abstract][Full Text] [Related]
2. Fluorescent Dopamine-Tryptophan Nanocomposites as Dual-Imaging and Antiaggregation Agents: New Generation of Amyloid Theranostics with Trimeric Effects.
Sharma M; Tiwari V; Shukla S; Panda JJ
ACS Appl Mater Interfaces; 2020 Sep; 12(39):44180-44194. PubMed ID: 32870652
[TBL] [Abstract][Full Text] [Related]
3. Anti-amyloidogenic amphipathic arginine-dehydrophenylalanine spheres capped selenium nanoparticles as potent therapeutic moieties for Alzheimer's disease.
Kour A; Tiwari V; Aggarwal N; Sekhar Panda H; Kumar A; Tiwari S; Chauhan VS; Shukla S; Panda JJ
Nanoscale; 2023 Aug; 15(30):12748-12770. PubMed ID: 37477348
[TBL] [Abstract][Full Text] [Related]
4. Tryptophan-galactosylamine conjugates inhibit and disaggregate amyloid fibrils of Aβ42 and hIAPP peptides while reducing their toxicity.
Paul A; Frenkel-Pinter M; Escobar Alvarez D; Milordini G; Gazit E; Zacco E; Segal D
Commun Biol; 2020 Sep; 3(1):484. PubMed ID: 32879439
[TBL] [Abstract][Full Text] [Related]
5. Sialic acid (SA)-modified selenium nanoparticles coated with a high blood-brain barrier permeability peptide-B6 peptide for potential use in Alzheimer's disease.
Yin T; Yang L; Liu Y; Zhou X; Sun J; Liu J
Acta Biomater; 2015 Oct; 25():172-83. PubMed ID: 26143603
[TBL] [Abstract][Full Text] [Related]
6. Design of LVFFARK and LVFFARK-functionalized nanoparticles for inhibiting amyloid β-protein fibrillation and cytotoxicity.
Xiong N; Dong XY; Zheng J; Liu FF; Sun Y
ACS Appl Mater Interfaces; 2015 Mar; 7(10):5650-62. PubMed ID: 25700145
[TBL] [Abstract][Full Text] [Related]
7. Functional Characteristics and Molecular Mechanism of a New scFv Antibody Against Aβ42 Oligomers and Immature Protofibrils.
Zhang Y; Sun Y; Huai Y; Zhang YJ
Mol Neurobiol; 2015 Dec; 52(3):1269-1281. PubMed ID: 25330935
[TBL] [Abstract][Full Text] [Related]
8. Structural variation in amyloid-β fibrils from Alzheimer's disease clinical subtypes.
Qiang W; Yau WM; Lu JX; Collinge J; Tycko R
Nature; 2017 Jan; 541(7636):217-221. PubMed ID: 28052060
[TBL] [Abstract][Full Text] [Related]
9. Rationally designed peptide-based inhibitor of Aβ42 fibril formation and toxicity: a potential therapeutic strategy for Alzheimer's disease.
Horsley JR; Jovcevski B; Wegener KL; Yu J; Pukala TL; Abell AD
Biochem J; 2020 Jun; 477(11):2039-2054. PubMed ID: 32427336
[TBL] [Abstract][Full Text] [Related]
10. Antagonistic Activity of Naphthoquinone-Based Hybrids toward Amyloids Associated with Alzheimer's Disease and Type-2 Diabetes.
Paul A; Viswanathan GK; Mahapatra S; Balboni G; Pacifico S; Gazit E; Segal D
ACS Chem Neurosci; 2019 Aug; 10(8):3510-3520. PubMed ID: 31282646
[TBL] [Abstract][Full Text] [Related]
11. Non-toxic conformer of amyloid β may suppress amyloid β-induced toxicity in rat primary neurons: implications for a novel therapeutic strategy for Alzheimer's disease.
Izuo N; Murakami K; Sato M; Iwasaki M; Izumi Y; Shimizu T; Akaike A; Irie K; Kume T
Biochem Biophys Res Commun; 2013 Aug; 438(1):1-5. PubMed ID: 23747423
[TBL] [Abstract][Full Text] [Related]
12. The Anti-Amyloidogenic Action of Doxycycline: A Molecular Dynamics Study on the Interaction with Aβ42.
Gautieri A; Beeg M; Gobbi M; Rigoldi F; Colombo L; Salmona M
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31546787
[TBL] [Abstract][Full Text] [Related]
13. Scrutiny of the mechanism of small molecule inhibitor preventing conformational transition of amyloid-β
Shuaib S; Goyal B
J Biomol Struct Dyn; 2018 Feb; 36(3):663-678. PubMed ID: 28162045
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's Aβ42 and Aβ40 peptides form interlaced amyloid fibrils.
Gu L; Guo Z
J Neurochem; 2013 Aug; 126(3):305-11. PubMed ID: 23406382
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Alzheimer's amyloid-β
Narang SS; Goyal D; Goyal B
J Biomol Struct Dyn; 2020 Apr; 38(6):1598-1611. PubMed ID: 31046642
[TBL] [Abstract][Full Text] [Related]
16. Coassembled Chitosan-Hyaluronic Acid Nanoparticles as a Theranostic Agent Targeting Alzheimer's β-Amyloid.
Wang W; Liu M; Gao W; Sun Y; Dong X
ACS Appl Mater Interfaces; 2021 Dec; 13(47):55879-55889. PubMed ID: 34786930
[TBL] [Abstract][Full Text] [Related]
17. Futuristic Alzheimer's therapy: acoustic-stimulated piezoelectric nanospheres for amyloid reduction.
Sharma M; Choudhury S; Babu A; Gupta V; Sengupta D; Ali SA; Dhokne MD; Datusalia AK; Mandal D; Panda JJ
Biomater Sci; 2024 Mar; 12(7):1801-1821. PubMed ID: 38407241
[TBL] [Abstract][Full Text] [Related]
18. Protection mechanisms against Abeta42 aggregation.
Yan Y; Wang C
Curr Alzheimer Res; 2008 Dec; 5(6):548-54. PubMed ID: 19075581
[TBL] [Abstract][Full Text] [Related]
19. Discovery and Identification of an Endogenous Metabolite of Tramiprosate and Its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in the Human Brain.
Hey JA; Kocis P; Hort J; Abushakra S; Power A; Vyhnálek M; Yu JY; Tolar M
CNS Drugs; 2018 Sep; 32(9):849-861. PubMed ID: 30076539
[TBL] [Abstract][Full Text] [Related]
20. Hydroxylated Single-Walled Carbon Nanotubes Inhibit Aβ
Liu F; Wang W; Sang J; Jia L; Lu F
ACS Chem Neurosci; 2019 Jan; 10(1):588-598. PubMed ID: 30335950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
